Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Oncostellae logo — Novel small-molecule drugs in immunology, fibrosis and women...

Oncostellae

Novel small-molecule drugs in immunology, fibrosis and women health

Founded 2013 Spain Spain 10 employees Series A Total: $4.30M Health Care, Pharmaceutical

General Information

Company Name Oncostellae
Founded Year 2013
Location Spain Spain
Founders / Decision Makers
Team member
Employees 10
Industries Health Care, Pharmaceutical
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Oncostellae. To contact Oncostellae, visit oncostellae.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Oncostellae compare?

A PDF of Oncostellae and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Oncostellae soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Oncostellae

Oncostellae, a clinical-stage biotech company based in Spain, is making strides in the development of novel small-molecule drugs targeted at treating oncology and inflammatory/autoimmune diseases. Founded in 2013 by serial entrepreneurs, the company has garnered support from private & institutional investors, with the latest Venture Round investment secured on 18 March 2024 from CDTI, Bio&Tech Smart Capital. Oncostellae's focus lies in the discovery and development of new chemical entities with robust IP and worldwide rights, particularly aiming at significant market indications in immunology and oncology. The company's promising pipeline includes two advanced drug candidates undergoing clinical evaluation. OST-122, a safe, non-systemic JAK inhibitor, is being studied in Phase 2a trials for the treatment of Ulcerative Colitis, while OST-499, a GR antagonist, is in Phase 1 trials intended for the treatment of colon cancer and other solid tumors. Moreover, Oncostellae anticipates the availability of positive safety and efficacy data by the end of 2023, which is expected to create outlicensing opportunities. These developments position the company for prospective license agreements with pharmaceutical firms for continued clinical development and commercialization. With a compelling focus on addressing critical unmet medical needs within the pharmaceutical industry, Oncostellae's innovative drug candidates and strong investor support indicate a promising trajectory for the company.

Business keywords: Clinical-stage biotech company, Small-molecule drugs, Oncology, Inflammatory diseases, Autoimmune diseases, Discovery and development, Chemical entities, IP rights, Immunology, Licensing agreements, Pharmaceutical companies, JAK inhibitor, Ulcerative colitis, GR antagonist, Colon cancer

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series A Undisclosed 2
Bio&Tech Smart Capital
Bio&Tech Smart Capital, Centre for the Development of Industrial Technology (CDTI)
18 Mar 2024
Venture Round €3.30M 5
Inveready Xesgalicia Fitalent
Inveready, Xesgalicia +3
23 Nov 2022
Venture Round Undisclosed 1
Fitalent
Fitalent
01 Jan 2017
Seed Round $1.00M 1
Inveready
Inveready
12 Feb 2016

Oncostellae Alternatives & Competitors

Oncostellae vs
Redx Pharma
Redx Pharma United Kingdom

Biotech company focusing on the discovery and development of novel targeted medicines to treat cance...

Post-IPO Equity
39 employees
Biotechnology, Health Care
Oncostellae vs
BeBetter Med
BeBetter Med China

Clinical-stage drug discovery and development of advanced novel medicines for cancer and other sever...

Private Equity
5 employees
Health Care, Pharmaceutical
Oncostellae vs
Synta Pharmaceuticals
Synta Pharmaceuticals

Innovating patient care with advanced small molecule therapies for severe medical conditions, includ...

Post-IPO Equity
Biotechnology, Health Care

FAQ About Oncostellae

Novel small-molecule drugs in immunology, fibrosis and women health
Oncostellae was founded in 2013.
Oncostellae is headquartered in Spain.
Oncostellae operates in Health Care and Pharmaceutical. Its work centres on Clinical-stage biotech company, Small-molecule drugs, Oncology and Inflammatory diseases.
Oncostellae has approximately 10 employees.
Oncostellae has completed 4 funding rounds, raising a total of $4.30M. The latest funding stage is Series A.
Top alternatives and competitors to Oncostellae include Redx Pharma, BeBetter Med, Synta Pharmaceuticals, Tetralogic Pharmaceuticals, Cosmo Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Oncostellae and Redx Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Oncostellae, https://bouncewatch.com/company/oncostellae, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes